Prognosis of Cerebral Small Vessel Disease

NCT ID: NCT05734378

Last Updated: 2023-03-08

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

900 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-12-01

Study Completion Date

2030-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Prognosis of small vessel disease (SVD) depends on the underlying type of SVD and index manifestation.

The aim of this prospective, observational cohort study is to determine the risk of different outcome events among patients with SVD according to the type of index presentation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cerebral Amyloid Angiopathy Small Vessel Cerebrovascular Disease Cadasil CAA - Cerebral Amyloid Angiopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Hypertensive deep perforator arteriolopathy (DPA), clinically symptomatic with either ICH, ischaemic stroke, cognitive impairment or severe radiological manifestation (Fazekas ≥II)
* Cerebral amyloid angiopathy (CAA according to modified Boston or Edinburgh criteria), clinically symptomatic with either ICH (including cSAH), amyloid spells, cognitive impairment or severe radiological manifestation (CMB≥2)
* Other SVD (i.e. CADASIL or other sporadic or genetic SVD)

Exclusion Criteria

* Life expectancy of \<6 months due to not-SVD related causes (i.e. cancer)
* Patient is unlikely to attend follow-up visits
Minimum Eligible Age

16 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Insel Gruppe AG, University Hospital Bern

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

David J Seiffge, Prof, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Neurology, Inselspital Bern University Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Department of Neurology, Inselspital Bern University Hospital

Bern, , Switzerland

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Switzerland

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Marianne Kormann

Role: CONTACT

+41 31 632 70 00

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

David J Seiffge, MD, Prof

Role: primary

+41 31 632 70 00

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2020-02535

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Swiss SOS MoCA - DCI Study
NCT03032471 TERMINATED